Rationale and design of the multicenter, national, randomized, open labeled phase III trial: allogeneic stem cell transplantation as a potential curative treatment for patients with relapsed or progressed multiple myeloma (AlloRelapseMM Study)
Authors
Nicolaus Martin Kröger (ORCID: https://orcid.org/0000-0001-5103-9966)
Hermann Einsele (ORCID: https://orcid.org/0000-0002-7680-0819)
Stefan Schönland (ORCID: https://orcid.org/0000-0002-4853-5579)
Rationale and design of the multicenter, national, randomized, open labeled phase III trial: allogeneic stem cell transplantation as a potential curative treatment for patients with relapsed or progressed multiple myeloma (AlloRelapseMM Study)
Nicolaus Martin Kröger, Hermann Einsele, Stefan Schönland, A. Glöckner
Citations
1 citations
Journal
BMC Cancer
Topics
Multiple Myeloma Research and Treatments
Field-Weighted Citation Impact (FWCI)
1.77
article
Rationale and design of the multicenter, national, randomized, open labeled phase III trial: allogeneic stem cell transplantation as a potential curative treatment for patients with relapsed or progressed multiple myeloma (AlloRelapseMM Study)
Nicolaus Martin Kröger, Hermann Einsele, Stefan Schönland, A. Glöckner
article en
1 citations
Abstract
No abstract available for this paper.
Publication Tag
BMC CancerVol. 25(1)
Institutions
Universität Hamburg (DE), Heidelberg University (DE), University Hospital Heidelberg (DE), University Medical Center Hamburg-Eppendorf (DE), Universitätsklinikum Würzburg (DE)